TY - JOUR
T1 - Imaging in population science
T2 - Cardiovascular magnetic resonance in 100,000 participants of UK Biobank - Rationale, challenges and approaches
AU - Petersen, Steffen E.
AU - Matthews, Paul M.
AU - Bamberg, Fabian
AU - Bluemke, David A.
AU - Francis, Jane M.
AU - Friedrich, Matthias G.
AU - Leeson, Paul
AU - Nagel, Eike
AU - Plein, Sven
AU - Rademakers, Frank E.
AU - Young, Alistair A.
AU - Garratt, Steve
AU - Peakman, Tim
AU - Sellors, Jonathan
AU - Collins, Rory
AU - Neubauer, Stefan
N1 - Funding Information:
SEP was directly funded by the National Institute for Health Research Cardiovascular Biomedical Research Unit at Barts. SN acknowledges support from the Oxford NIHR Biomedical Research Centre and from the Oxford British Heart Foundation Centre of Research Excellence. SP and PL are funded by a BHF Senior Clinical Research fellowship. RC is supported by a BHF Research Chair and acknowledges the support of the Oxford BHF Centre for Research Excellence and the MRC and Wellcome Trust. PMM gratefully acknowledges training fellowships supporting his laboratory from the Wellcome Trust, GlaxoSmithKline and the Medical Research Council. We would like to thank the Clinical Trials Committee of the Society for Cardiovascular Magnetic Resonance (SCMR), the British Society of Cardiovascular Magnetic Resonance Research Group, the ESC Working Group on Cardiovascular Magnetic Resonance, members of the UK Biobank Imaging Working Group and members of the UK Biobank coordinating centre and many others for their invaluable contributions to this topic in numerous discussions.
Funding Information:
SP receives grant support from Philips Healthcare. PMM is a part-time employee of GlaxoSmithKline Research and Development, Ltd.
Funding Information:
1Centre Lead for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Unit at Barts, The London Chest Hospital, Bonner Road, London E2 9JX, UK. 2Division of Brain Sciences, Department of Medicine, Imperial College, London, UK. 3GlaxoSmithKline Research and Development, Ltd, Munich, Germany. 4Department of Radiology, Ludwig-Maximilians University Munich, Munich, Germany. 5Radiology and Imaging Sciences, NIH Clinical Center, Oxford, UK. 6Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. 7Montreal Heart Institute, Université de Montréal and University of Calgary, Calgary, Canada. 8King’s College London British Heart Foundation Centre of Excellence; National Institute of Health Research (NIHR) Biomedical Research Centre at Guy’s and St. Thomas’ (NHS) Foundation Trust; Wellcome Trust and Engineering and Physical Sciences Research Council (EPSRC) Medical Engineering Centre; Division of Imaging Sciences; The Rayne Institute, St. Thomas’ Hospital, London, UK. 9Multidisciplinary Cardiovascular Research Centre & Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, UK. 10University Hospitals Leuven, Leuven, KU, Belgium. 11Department of Anatomy with Radiology, University of Auckland, Auckland, UK. 12UK Biobank, Spectrum Way, Adswood, Stockport, Cheshire SK3 0SA, UK.
PY - 2013
Y1 - 2013
N2 - UK Biobank is a prospective cohort study with 500,000 participants aged 40 to 69. Recently an enhanced imaging study received funding. Cardiovascular magnetic resonance (CMR) will be part of a multi-organ, multi-modality imaging visit in 3-4 dedicated UK Biobank imaging centres that will acquire and store imaging data from 100,000 participants (subject to successful piloting). In each of UK Biobank's dedicated bespoke imaging centres, it is proposed that 15-20 participants will undergo a 2 to 3 hour visit per day, seven days a week over a period of 5-6 years. The imaging modalities will include brain MRI at 3 Tesla, CMR and abdominal MRI at 1.5 Tesla, carotid ultrasound and DEXA scans using carefully selected protocols. We reviewed the rationale, challenges and proposed approaches for concise phenotyping using CMR on such a large scale. Here, we discuss the benefits of this imaging study and review existing and planned population based cardiovascular imaging in prospective cohort studies. We will evaluate the CMR protocol, feasibility, process optimisation and costs. Procedures for incidental findings, quality control and data processing and analysis are also presented. As is the case for all other data in the UK Biobank resource, this database of images and related information will be made available through UK Biobank's Access Procedures to researchers (irrespective of their country of origin and whether they are academic or commercial) for health-related research that is in the public interest.
AB - UK Biobank is a prospective cohort study with 500,000 participants aged 40 to 69. Recently an enhanced imaging study received funding. Cardiovascular magnetic resonance (CMR) will be part of a multi-organ, multi-modality imaging visit in 3-4 dedicated UK Biobank imaging centres that will acquire and store imaging data from 100,000 participants (subject to successful piloting). In each of UK Biobank's dedicated bespoke imaging centres, it is proposed that 15-20 participants will undergo a 2 to 3 hour visit per day, seven days a week over a period of 5-6 years. The imaging modalities will include brain MRI at 3 Tesla, CMR and abdominal MRI at 1.5 Tesla, carotid ultrasound and DEXA scans using carefully selected protocols. We reviewed the rationale, challenges and proposed approaches for concise phenotyping using CMR on such a large scale. Here, we discuss the benefits of this imaging study and review existing and planned population based cardiovascular imaging in prospective cohort studies. We will evaluate the CMR protocol, feasibility, process optimisation and costs. Procedures for incidental findings, quality control and data processing and analysis are also presented. As is the case for all other data in the UK Biobank resource, this database of images and related information will be made available through UK Biobank's Access Procedures to researchers (irrespective of their country of origin and whether they are academic or commercial) for health-related research that is in the public interest.
KW - Biobank
KW - Cardiovascular magnetic resonance
KW - Nested-case control study
KW - Population-based study
KW - Prospective cohort study
UR - http://www.scopus.com/inward/record.url?scp=84878253707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878253707&partnerID=8YFLogxK
U2 - 10.1186/1532-429X-15-46
DO - 10.1186/1532-429X-15-46
M3 - Review article
C2 - 23714095
AN - SCOPUS:84878253707
SN - 1097-6647
VL - 15
JO - Journal of Cardiovascular Magnetic Resonance
JF - Journal of Cardiovascular Magnetic Resonance
IS - 1
M1 - 46
ER -